Therapeutic administration of hCG in pregnant women with preeclamptic risk

摘要

Recent studies revealed functional extiagonadal gonadotiopin receptors in the human body: fallopian tube, myometiium, endometrium, cervix, uterine and spiialate arteries, breast, umbilical cord, etc The human hCG/LH receptor mRNA and protein were found in endothelial and vascular smooth muscle layers of uterine arteries, more abundant in the spiral arteries, therefore in the part of uterine circulation important in regulation of vascular resistance In vivo hCG administration decreased blood flow resistance in human uterus and in vitro hGG increased vasodilating eicosanoids levels in vascular walls Nevertheless, beginning with the 16th week of gestation, there is a spectacular growth of the human fetal brain, forcing placenta to a second tiophoblastic wave of invasion which targets spiralate myometrial arteries This process calls foi angiogenetic factors such as VEGF and P1GF Recently, it was documented that hCG provides angiogenetic stimulus These data initiated the study presented here The question raised was whether hCG treatment can improve clinical outcome in pregnant women over their 20th week of gestation with preeclamptic risk.